ANIP · ANI Pharmaceuticals Inc
United States · RS rating 40 · As of 2026-11-03
| Price | 72.28 USD |
|---|---|
| 1-day change | +2.3% |
| RS rating (overall / 1M / 3M / 12M) | 40 / 55 / 47 / 36 |
| Stage | Declining |
| Composite / Minervini / CANSLIM score | 26 / 18 / 25 |
| Industry group (rank) | Medical-Generic Drugs (136) |
| EPS growth Q/Q | +4.4% |
| Sales growth Q/Q | +8.4% |
| Distance from 52-week high | +23.5% |
| Market cap (USD) | $1.8B |